TransMedics Group (NASDAQ:TMDX) Director David Weill Sells 3,571 Shares

TransMedics Group, Inc. (NASDAQ:TMDX) Director David Weill sold 3,571 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $146.82, for a total transaction of $524,294.22. Following the sale, the director directly owned 12,134 shares of the company’s stock, valued at $1,781,513.88. The trade was a 22.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

TransMedics Group Stock Performance

TMDX opened at $129.80 on Friday. TransMedics Group, Inc. has a twelve month low of $62.23 and a twelve month high of $156.00. The firm has a market capitalization of $4.45 billion, a PE ratio of 26.49 and a beta of 1.98. The company has a current ratio of 7.14, a quick ratio of 6.59 and a debt-to-equity ratio of 1.06. The firm’s 50-day moving average price is $135.35 and its 200 day moving average price is $126.90.

Hedge Funds Weigh In On TransMedics Group

Several hedge funds have recently bought and sold shares of the company. Intech Investment Management LLC boosted its stake in shares of TransMedics Group by 28.9% in the second quarter. Intech Investment Management LLC now owns 34,389 shares of the company’s stock valued at $4,608,000 after purchasing an additional 7,713 shares during the period. Nordea Investment Management AB purchased a new stake in TransMedics Group during the 3rd quarter worth approximately $4,070,000. Peregrine Capital Management LLC lifted its holdings in TransMedics Group by 16.5% during the 3rd quarter. Peregrine Capital Management LLC now owns 68,406 shares of the company’s stock worth $7,675,000 after buying an additional 9,676 shares in the last quarter. Intrust Bank NA purchased a new position in TransMedics Group in the 2nd quarter valued at approximately $747,000. Finally, Citigroup Inc. grew its stake in shares of TransMedics Group by 29.3% in the third quarter. Citigroup Inc. now owns 76,785 shares of the company’s stock worth $8,615,000 after acquiring an additional 17,414 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on TMDX. Piper Sandler upped their price target on TransMedics Group from $140.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Oppenheimer boosted their price objective on TransMedics Group from $150.00 to $175.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. JPMorgan Chase & Co. upped their target price on TransMedics Group from $114.00 to $149.00 and gave the company a “neutral” rating in a report on Wednesday, February 25th. Morgan Stanley raised their target price on TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 2nd. Finally, Wall Street Zen cut shares of TransMedics Group from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Six analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $150.67.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.